Skip to main content
TipRanks
Go Ultimate75% OFF

Vivoryon Therapeutics AG (VVY) AI Stock Analysis

2 Followers
NL:VVY

Vivoryon Therapeutics AG

(Amsterdam:VVY)

Select Model
Rating:40Underperform
Price Target:EUR 0.73â–²(3.10% Upside)
Action:reiterated
Date:11/12/26

The overall score is heavily pressured by the company's pre-revenue status and ongoing cash burn, despite improved cost controls. Technicals confirm a sustained downtrend, and the negative P/E offers no valuation support. The primary risk remains the need for future dilutive financing.

Positive Factors
Low LeverageVery low leverage limits fixed financial obligations and reduces the balance-sheet burden from debt. This provides more flexibility than a highly indebted structure, although the benefit is tempered by the company’s declining equity base and continuing cash needs.
Negative Factors
No Recent Revenue and Persistent LossesThe absence of reported revenue in 2024–2025, together with negative gross profit and continuing operating losses, shows that the business has not yet established commercial earnings power. This leaves future financial sustainability dependent on successful development and eventual monetization.

Vivoryon Therapeutics AG (VVY) vs. iShares MSCI Netherlands ETF (EWN)

-80%-60%-40%-20%0%20%40%NL:VVY-55.63%EWN+14.26%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
EUR 19.60M
Dividend Yield
―
Average Volume (3M)
58.24K
Price to Earnings (P/E)
-3.1
Beta (1Y)
0.56
Revenue Growth
―
EPS Growth
51.44%
Country
Netherlands
Employees
13
Sector
General
Sector Strength
55
Industry
Biotechnology

Vivoryon Therapeutics AG Business Overview & Revenue Model

Company Description

Vivoryon Therapeutics N.V. is a clinical-stage biopharmaceutical firm dedicated to discovering and developing novel treatments for Alzheimer's disease. The company's therapeutic pipeline primarily focuses on mitigating Alzheimer's by targeting and pr...

Vivoryon Therapeutics AG Earnings Call Summary

Earnings Call Date:Sep 04, 2025(Q2-2025)|% Change Since:-58.38%|Next Earnings Date:Nov 28, 2019
Earnings Call SentimentNeutral

The earnings call highlighted significant clinical and financial progress, particularly in reducing expenses and advancing the varoglutamstat program, while also addressing challenges such as a reduced cash position and the need for additional financing for future studies.

Positive Updates

Significant Reduction in R&D Expenses
Research and development expenses decreased by EUR 7.5 million, from EUR 10.3 million in the first half of 2024 to EUR 2.8 million in the first half of 2025, largely due to a decrease in clinical development and production costs.

Negative Updates

Decreased Cash Position
Vivoryon's cash and cash equivalents decreased to EUR 4.8 million as of June 30, 2025, from EUR 9.4 million at the end of 2024, raising concerns about future funding.

Company Guidance

In the recent call discussing Vivoryon's first half 2025 results, several key metrics and achievements were highlighted. Research and development expenses for the period were EUR 2.8 million, a significant reduction from EUR 10.3 million in the first half of 2024, primarily due to decreased clinical development costs and production expenses. General and administrative expenses also saw a decline to EUR 2.8 million from EUR 3.5 million in the previous year. Consequently, the net loss for the first half of 2025 was reduced to EUR 5.5 million, compared to EUR 13.6 million in the same period of 2024. The company reported holding EUR 4.8 million in cash and cash equivalents as of June 30, 2025, with a cash runway extending into January 2026, excluding funds from a standby equity purchase agreement. Vivoryon also secured U.S. patents for varoglutamstat, ensuring market exclusivity through 2044. The company presented compelling kidney function data from its Phase II studies at the European Renal Association Annual Congress, showcasing statistically significant improvements in kidney function with varoglutamstat compared to placebo. Preparations for a dedicated Phase IIb study in diabetic kidney disease are underway, highlighting Vivoryon's strategic focus on expanding its therapeutic impact in the kidney disease market.

Vivoryon Therapeutics AG Financial Statement Overview

Summary

Pre-revenue biotech with persistent net losses and negative cash flows, though the burn rate has improved significantly. Minimal debt provides some stability, but thin equity and the need for future capital raises weigh heavily on the score.

Income Statement

20Very Negative

Balance Sheet

30Negative

Cash Flow

25Negative
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue000-3.62M010.76M
Gross Profit-141.00K-147.00K-147.00K-3.10M-161.00K9.03M
EBITDA-6.90M-9.03M-20.34M-28.35M-28.17M-12.03M
Net Income-6.77M-8.85M-20.57M-28.34M-28.16M-12.65M
Balance Sheet
Total Assets4.17M7.52M11.28M30.83M31.38M24.52M
Cash, Cash Equivalents and Short-Term Investments2.45M5.62M9.37M28.58M26.55M14.66M
Total Debt76.00K108.00K102.00K38.00K132.00K224.00K
Total Liabilities2.60M2.79M3.40M4.55M4.87M7.96M
Stockholders Equity1.56M4.73M7.88M26.28M26.51M16.56M
Cash Flow
Free Cash Flow-7.11M-8.46M-19.18M-22.05M-21.81M-11.29M
Operating Cash Flow-7.10M-8.46M-19.17M-21.54M-21.79M-11.26M
Investing Cash Flow2,000-6,00010.00M-10.51M-13.00K-28.00K
Financing Cash Flow4.71M4.71M-57.00K24.16M33.38M-827.00K

Vivoryon Therapeutics AG Technical Analysis

Technical Analysis SentimentNegative
Last Price0.71

Price Trends

50DMA0.95Negative
100DMA1.06Negative
200DMA1.18Negative

Market Momentum

MACD-0.07Negative
RSI39.77Neutral
STOCH56.41Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NL:VVY, the sentiment is Negative. The current price of 0.71 is below the 20-day moving average (MA) of 0.78, below the 50-day MA of 0.95, and below the 200-day MA of 1.18, indicating a bearish trend. The MACD of -0.07 indicates Negative momentum. The RSI at 39.77 is Neutral, neither overbought nor oversold. The STOCH value of 56.41 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for NL:VVY.

Vivoryon Therapeutics AG Peers Comparison

Overall Rating

UnderperformOutperform
Sector (55)

Financial Indicators

NL:VVY against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
NL:LKFTNL:LKFT74OutperformEUR 2.07B4.2616.88%―223.08%―
NL:PHARMNL:PHARM73OutperformEUR 793.78M35.078.96%―1.73%―
NL:CRBNNL:CRBN68NeutralEUR 1.51B24.318.30%3.81%-3.37%-8.22%
NL:DSFIRNL:DSFIR62NeutralEUR 24.81B-21.49―2.41%-44.75%-301.20%
Sector *55Neutral$6.65B3.83-15.92%6.20%10.91%7.18%
NL:AVTXNL:AVTX41NeutralEUR 101.15M-1.14-25.04%―-32.85%26.72%
NL:VVYNL:VVY40UnderperformEUR 21.03M-3.09-215.13%――51.44%

* General Sector Average

Performance Comparison

-50%0%50%NL:VVYNL:PHARMNL:AVTXNL:CRBNNL:LKFTNL:DSFIRDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
NL:VVY and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
NL:VVYVivoryon Therapeutics AG0.71-0.92-56.33%
NL:PHARMPharming Group N.V.1.12-0.27-19.29%
NL:AVTXAvantium N.V.1.70-2.45-58.93%
NL:CRBNCorbion NV26.268.6048.72%
NL:LKFTLakefront Biotherapeutics Nv31.464.9818.81%
NL:DSFIRDSM-Firmenich AG103.6036.5954.60%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 12, 2026